Synthesis and Evaluation of New 1,3,4-Thiadiazole-Benzimidazole Hybrids as Potent Antibacterial Agents

Wejdan Khaled Harat and Muayad Ahmed Rdaiaan

References:

1. J. L. Martínez and F. Baquero, "Emergence and spread of antibiotic resistance: setting a parameter space," Ups. J. Med. Sci., vol. 119, no. 2, pp. 68-77, 2014, [Online]. Available: https://doi.org/10.3109/03009734.2014.901444.
2. M. Woolhouse, C. Waugh, M. R. Perry, and H. Nair, "Global disease burden due to antibiotic resistance – state of the evidence," J. Glob. Health, vol. 6, no. 1, p. 010306, 2016, [Online]. Available: https://doi.org/10.7189/JOGH.06.010306.
3. J. Vila et al., "Escherichia coli: an old friend with new tidings," FEMS Microbiol. Rev., vol. 40, no. 4, pp. 437-463, Jul. 2016, [Online]. Available: https://doi.org/10.1093/FEMSRE/FUW005.
4. J. D. D. Pitout, "Extraintestinal pathogenic Escherichia coli: an update on antimicrobial resistance, laboratory diagnosis and treatment," Expert Rev. Anti. Infect. Ther., vol. 10, no. 10, pp. 1165-1176, Oct. 2012, [Online]. Available: https://doi.org/10.1586/ERI.12.110.
5. P. Vikesland, E. Garner, S. Gupta, S. Kang, A. Maile-Moskowitz, and N. Zhu, "Differential Drivers of Antimicrobial Resistance across the World," Acc. Chem. Res., vol. 52, no. 4, pp. 916-924, Apr. 2019, [Online]. Available: https://doi.org/10.1021/ACS.ACCOUNTS.8B00643.
6. A. R. Brochado et al., "Species-specific activity of antibacterial drug combinations," Nature, vol. 559, no. 7713, pp. 259-263, Jul. 2018, [Online]. Available: https://doi.org/10.1038/s41586-018-0278-9.
7. Q. Xin et al., "Antibacterial Carbon-Based Nanomaterials," Adv. Mater., vol. 31, no. 45, p. 1804838, Nov. 2019, [Online]. Available: https://doi.org/10.1002/ADMA.201804838.
8. X. Chen et al., "Synthesis and molecular docking studies of xanthone attached amino acids as potential antimicrobial and anti-inflammatory agents," Med. Chem. Commun., vol. 8, no. 8, pp. 1706-1719, Aug. 2017, [Online]. Available: https://doi.org/10.1039/C7MD00209B.
9. M. Xu, P. Wu, F. Shen, J. Ji, and K. P. Rakesh, "Chalcone derivatives and their antibacterial activities: Current development," Bioorg. Chem., vol. 91, p. 103133, Oct. 2019, [Online]. Available: https://doi.org/10.1016/J.BIOORG.2019.103133.
10. M. J. Tebbe et al., "Antirhino/Enteroviral Vinylacetylene Benzimidazoles: A Study of Their Activity and Oral Plasma Levels in Mice," J. Med. Chem., vol. 40, no. 24, pp. 3937-3946, 1997, [Online]. Available: https://doi.org/10.1021/JM970423K.
11. V. V. Zarubaev, A. S. Morkovnik, L. N. Divaeva, L. A. Karpinskaya, and G. S. Borodkin, "Tautomeric and non-tautomeric N-substituted 2-iminobenzimidazolines as new lead compounds for the design of anti-influenza drugs: An in vitro study," Bioorg. Med. Chem., vol. 24, no. 22, pp. 5796-5803, Nov. 2016, [Online]. Available: https://doi.org/10.1016/J.BMC.2016.09.036.
12. M. T. Migawa et al., "Design, Synthesis, and Antiviral Activity of α-Nucleosides: d- and l-Isomers of Lyxofuranosyl- and (5-Deoxylyxofuranosyl)benzimidazoles," J. Med. Chem., vol. 41, no. 8, pp. 1242-1251, Apr. 1998, [Online]. Available: https://doi.org/10.1021/JM970545C.
13. A. R. Porcari, R. V. Devivar, L. S. Kucera, J. C. Drach, and L. B. Townsend, "Design, Synthesis, and Antiviral Evaluations of 1-(Substituted benzyl)-2-substituted-5,6-dichlorobenzimidazoles as Nonnucleoside Analogues of 2,5,6-Trichloro-1-(β-d-ribofuranosyl)benzimidazole," J. Med. Chem., vol. 41, no. 8, pp. 1252-1262, Apr. 1998, [Online]. Available: https://doi.org/10.1021/JM970559I.
14. W. A. Denny, G. W. Rewcastle, and B. C. Baguley, "Potential Antitumor Agents. 59. Structure-Activity Relationships for 2-Phenylbenzimidazole-4-carboxamides, a New Class of ‘Minimal’ DNA-Intercalating Agents Which May Not Act via Topoisomerase II," J. Med. Chem., vol. 33, no. 2, pp. 814-819, 1990, [Online]. Available: https://doi.org/10.1021/JM00164A054.
15. T. Fonseca, B. Gigante, and T. L. Gilchrist, "A short synthesis of phenanthro[2,3-d]imidazoles from dehydroabietic acid. Application of the methodology as a convenient route to benzimidazoles," Tetrahedron, vol. 57, no. 9, pp. 1793-1799, Feb. 2001, [Online]. Available: https://doi.org/10.1016/S0040-4020(00)01158-3.
16. M. Cindrić et al., "Novel amidino substituted benzimidazole and benzothiazole benzo[b]thieno-2-carboxamides exert strong antiproliferative and DNA binding properties," Eur. J. Med. Chem., vol. 136, pp. 468-479, Aug. 2017, [Online]. Available: https://doi.org/10.1016/J.EJMECH.2017.05.014.
17. H. Gmunder, K. Kuratli, and W. Keck, "Effect of pyrimido[1,6-a]benzimidazoles, quinolones, and Ca²⁺ on the DNA gyrase-mediated cleavage reaction," Antimicrob. Agents Chemother., vol. 39, no. 1, pp. 163-169, 1995, [Online]. Available: https://doi.org/10.1128/AAC.39.1.163.
18. M. V. Papadopoulou, W. D. Bloomer, and H. S. Rosenzweig, "The antitubercular activity of various nitro(triazole/imidazole)-based compounds," Bioorg. Med. Chem., vol. 25, no. 21, pp. 6039-6048, Nov. 2017, [Online]. Available: https://doi.org/10.1016/J.BMC.2017.09.037.
19. A. Ç. g. Karaburun et al., "Synthesis and Antifungal Potential of Some Novel Benzimidazole-1,3,4-Oxadiazole Compounds," Molecules, vol. 24, no. 1, p. 191, Jan. 2019, [Online]. Available: https://doi.org/10.3390/MOLECULES24010191.
20. Y. Shi et al., "Design, Microwave-Assisted Synthesis and in Vitro Antibacterial and Antifungal Activity of 2,5-Disubstituted Benzimidazole," Chem. Biodivers., vol. 16, no. 3, p. e1800510, Mar. 2019, [Online]. Available: https://doi.org/10.1002/CBDV.201800510.
21. F. Naaz et al., "Molecular modeling, synthesis, antibacterial and cytotoxicity evaluation of sulfonamide derivatives of benzimidazole, indazole, benzothiazole and thiazole," Bioorg. Med. Chem., vol. 26, no. 12, pp. 3414-3428, Jul. 2018, [Online]. Available: https://doi.org/10.1016/J.BMC.2018.05.015.
22. F. F. Al-blewi et al., "Design, synthesis, ADME prediction and pharmacological evaluation of novel benzimidazole-1,2,3-triazole-sulfonamide hybrids as antimicrobial and antiproliferative agents," Chem. Cent. J., vol. 12, no. 1, pp. 1-14, Nov. 2018, [Online]. Available: https://doi.org/10.1186/S13065-018-0479-1.
23. K. Y. Yeong, C. W. Ang, M. A. Ali, H. Osman, and S. C. Tan, "Antituberculosis agents bearing the 1,2-disubstituted benzimidazole scaffold," Med. Chem. Res., vol. 26, no. 4, pp. 770-778, Apr. 2017, [Online]. Available: https://doi.org/10.1007/S00044-017-1784-2.
24. H. Z. Zhang et al., "Design, synthesis and antimicrobial evaluation of novel benzimidazole-incorporated sulfonamide analogues," Eur. J. Med. Chem., vol. 136, pp. 165-183, Aug. 2017, [Online]. Available: https://doi.org/10.1016/J.EJMECH.2017.04.077.
25. D. Mantu, V. Antoci, C. Moldoveanu, G. Zbancioc, and I. I. Mangalagiu, "Hybrid imidazole (benzimidazole)/pyridine (quinoline) derivatives and evaluation of their anticancer and antimycobacterial activity," J. Enzyme Inhib. Med. Chem., vol. 31, pp. 96-103, Nov. 2016, [Online]. Available: https://doi.org/10.1080/14756366.2016.1190711.
26. H. N. Dogan, A. Duran, S. Rollas, G. Sener, M. K. Uysal, and D. Gülen, "Synthesis of new 2,5-disubstituted-1,3,4-thiadiazoles and preliminary evaluation of anticonvulsant and antimicrobial activities," Bioorg. Med. Chem., vol. 10, no. 9, pp. 2893-2898, 2002, [Online]. Available: https://doi.org/10.1016/S0968-0896(02)00143-8.
27. S. Haider, M. S. Alam, and H. Hamid, "1,3,4-Thiadiazoles: A potent multi targeted pharmacological scaffold," Eur. J. Med. Chem., vol. 92, pp. 156-177, Mar. 2015, [Online]. Available: https://doi.org/10.1016/J.EJMECH.2014.12.035.
28. A. K. Jain, S. Sharma, A. Vaidya, V. Ravichandran, and R. K. Agrawal, "1,3,4-Thiadiazole and its Derivatives: A Review on Recent Progress in Biological Activities," Chem. Biol. Drug Des., vol. 81, no. 5, pp. 557-576, May 2013, [Online]. Available: https://doi.org/10.1111/CBDD.12125.
29. R. Kassamali and D. A. Sica, "Acetazolamide: A forgotten diuretic agent," Cardiol. Rev., vol. 19, no. 6, pp. 276-278, Nov. 2011, [Online]. Available: https://doi.org/10.1097/CRD.0B013E31822B4939.
30. H. Knothe, "Microbiological activity of cefazedone as compared to cefazolin and cephalothin," Arzneimittelforschung, vol. 29, no. 2a, pp. 378-381, Jan. 1979, [Online]. Available: https://europepmc.org/article/med/39575, [Accessed: 05 Mar. 2025].
31. F. Manetti et al., "A combination of docking/dynamics simulations and pharmacophoric modeling to discover new dual c-Src/Abl kinase inhibitors," J. Med. Chem., vol. 49, no. 11, pp. 3278-3286, Jun. 2006, [Online]. Available: https://doi.org/10.1021/JM060236Z.